$289.02
0.05% yesterday
NYSE, Feb 04, 10:14 pm CET
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Amgen Stock price

$289.02
+30.43 11.77% 1M
-36.20 11.13% 6M
+28.38 10.89% YTD
-32.95 10.23% 1Y
+66.91 30.12% 3Y
+67.21 30.30% 5Y
+137.57 90.84% 10Y
NYSE, Closing price Tue, Feb 04 2025
+0.15 0.05%
ISIN
US0311621009
Symbol
AMGN
Sector
Industry

Key metrics

Market capitalization $155.36b
Enterprise Value $206.74b
P/E (TTM) P/E ratio 37.01
EV/FCF (TTM) EV/FCF 32.91
EV/Sales (TTM) EV/Sales 6.40
P/S ratio (TTM) P/S ratio 4.81
P/B ratio (TTM) P/B ratio 20.64
Dividend yield 3.11%
Last dividend (FY24) $9.00
Revenue growth (TTM) Revenue growth 21.38%
Revenue (TTM) Revenue $32.32b
EBIT (operating result TTM) EBIT $6.51b
Free Cash Flow (TTM) Free Cash Flow $6.28b
Cash position $9.01b
EPS (TTM) EPS $7.81
P/S forward 4.68
EV/Sales forward 6.23
Short interest 2.13%
Show more

Create a Free Account to create an Amgen alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Amgen Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Amgen forecast:

16x Buy
46%
16x Hold
46%
3x Sell
9%

Analyst Opinions

35 Analysts have issued a Amgen forecast:

Buy
46%
Hold
46%
Sell
9%

Financial data from Amgen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
32,324 32,324
21% 21%
100%
- Direct Costs 12,858 12,858
81% 81%
40%
19,466 19,466
0% 0%
60%
- Selling and Administrative Expenses 1,619 1,619
40% 40%
5%
- Research and Development Expense 5,762 5,762
26% 26%
18%
12,085 12,085
1% 1%
37%
- Depreciation and Amortization 5,575 5,575
55% 55%
17%
EBIT (Operating Income) EBIT 6,510 6,510
25% 25%
20%
Net Profit 4,230 4,230
44% 44%
13%

In millions USD.

Don't miss a Thing! We will send you all news about Amgen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amgen Stock News

Neutral
Seeking Alpha
about 8 hours ago
Amgen, Inc. (NASDAQ:AMGN ) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President Murdo Gordon - EVP, Global Commercial Operations James Bradner - EVP, Research & Development Peter Griffith - EVP & CFO Conference Call Participants Yaron Werber - TD Cowen Courtney Breen - Bernstein Salveen Richter - Gold...
Positive
The Motley Fool
about 12 hours ago
Biotechnology specialist Amgen (AMGN 0.05%) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS of $5.08 and revenue of $8.88 billion, but Amgen reported $5.31 in EPS and $9.1 billion in revenue, showcasing double-digit year-on-year growth in both metrics.
Positive
Reuters
about 13 hours ago
Amgen posted a higher quarterly profit on Tuesday, driven by an 11% rise in product sales, and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.
More Amgen News

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Head office United States
CEO Robert Bradway
Employees 26,700
Founded 1980
Website www.amgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today